New RNA vaccine takes aim at malaria in first human test
NCT ID NCT05581641
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 30 times
Summary
This early-stage trial tested a new RNA-based vaccine designed to protect against malaria. Sixty healthy adults received different doses of the vaccine or a placebo to check for safety and to see if it triggers an immune response. The study focused on finding a safe dose and monitoring side effects like injection site pain or fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alliance for Multispecialty Research, LLC
Tempe, Arizona, 85281, United States
-
Alliance for Multispecialty Research, LLC
Las Vegas, Nevada, 89119, United States
-
Alliance for Multispecialty Research, LLC
Knoxville, Tennessee, 37909, United States
-
Clinical Trials of Texas, Inc.
San Antonio, Texas, 78229, United States
-
University of Maryland, Center for Vaccine Development
Baltimore, Maryland, 21201, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.